Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot trial of nab-paclitaxel + cisplatin + gemcitabine with paricalcitol in metastatic pancreatic adenocarcinoma
2017-004467-13Phase 2Unknown
- Sponsor
- Barts Health NHS Trust
- Start
- Jul 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paricalcitol, paclitaxel, cisplatin and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (2 arms), sponsored by Barts Health NHS Trust. Primary endpoint: Tumor response after paricalcitol addition. Status: unknown.
02
Drugs
paricalcitolpaclitaxelcisplatingemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2017-004467-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004467-13.